January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

In people with PA and no concerning features, treatment with high-dose oral B12 or injection B12 are both reasonable options.

A person who has the type of anemia with B12 deficiency and low B12 levels (called "megaloblastic anemia" with unusual white ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in gene therapy using adeno-associated virus vectors (AAV), specifically ...

I am 71 years old and was diagnosed with pernicious anemia in October 2024. My B12 and folate levels were low. My antiparietal antibodies were abnormal, but the ...

Dr. Reddy’s (NYSE:RDY) on Thursday announced a licensing agreement with China-based Shanghai Henlius Biotech (OTCPK:SGBCF) to jointly develop and market a biosimilar version of Darzalex, a multiple ...

ADMA Biologics' growth potential with Asceniv makes it a compelling Buy. Click here to find out why ADMA stock is a Strong ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company ...